Why the study?
Does dipyridamole prevent thromboembolic complications in patients with conditions characterized by reduced platelet survival?
Population
Patients with conditions characterized by a reduction in platelet survival, including heart valve…
Design
Review
Authors
Loading...
May support aspirin monotherapy preference; leaves open dipyridamole utility in narrow high-risk subgroups.
Does dipyridamole prevent thromboembolic complications in patients with conditions characterized by reduced platelet survival?
This review concludes that dipyridamole has limited clinical value as an antiplatelet agent and provides no demonstrated benefit when added to aspirin.
Rivey et al. (1984) studied this question.